did a new meta-analysis find trazodone cut depression scores by an smd of 0.365 across eight trials?
“Trasadone significantly reduces severity of depression compared to controls with the standardized mean difference of 0.365.”
a guest, Dr. Paul Sarkowski (clinician presenting the meta-analysis) said on Psychopharmacology and Psychiatry Updates, 2026-09-29, at 04:37. hear it in context → the speaker cited: a new meta-analysis.
the episode: Trazodone for Insomnia and Comorbid Depression (at 04:37). we link the show's own page; we do not re-host audio.
first, the part that holds
the effect size is right. the 2026 meta-analysis in Psychopharmacology reports that trazodone reduced depression severity on the Hamilton Depression Rating Scale with an SMD of -0.365 (95% CI -0.480 to -0.249, p < 0.001), which matches the 0.365 the speaker quoted, and the result is statistically significant.
what we found when we went and looked
we pulled the PubMed record for the meta-analysis the speaker described (PMID 41081841; Psychopharmacology 2026;243(3):457-473). its abstract reports the same number the speaker gave: Hamilton Depression Rating Scale SMD = -0.365, 95% CI -0.480 to -0.249, p < 0.001. the minus sign only shows the direction, and lower scores mean less depression. the abstract says ten randomized trials with 1,029 participants were included. it does not say how many of them fed the Hamilton analysis, and it does not say what the control arms were. the full text is paywalled and we could not open it, so we could not check the "eight trials" detail against the paper. because one clause of the claim sentence could not be checked, the headline has to be unverifiable, even though the number at the center of the claim matched the abstract exactly.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| a new meta-analysis found trazodone reduced depression severity on the Hamilton Depression Rating Scale versus controls with a standardized mean difference of 0.365 | confirmed | the abstract reports 'reduced depression severity (Hamilton Depression Rating Scale: SMD = -0.365, 95% CI: -0.480 to -0.249, p < 0.001)'. the negative sign shows the direction of the reduction, so the size matches the speaker's figure. limitation: the abstract does not say whether the controls were placebo, other drugs, or a mix. [1][2] |
| the reduction was statistically significant | confirmed | p < 0.001, and the 95% confidence interval (-0.480 to -0.249) does not cross zero. statistical significance is a different question from clinical size: an SMD around 0.37 is in the small-to-moderate range. [1][2] |
| the Hamilton result came from eight trials | unverifiable | the abstract says the review included ten RCTs (1,029 participants) and does not give a per-outcome trial count. the full text was paywalled when we tried it, so the 'eight trials' figure could not be checked against the paper. eight of ten fits with the abstract but is not confirmed by it. [1][2] |
| context: trazodone is an approved antidepressant, not only a sleep drug | confirmed | the FDA label text served by openFDA reads 'Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.' so an antidepressant effect on Hamilton scores is in line with what the drug is approved for. [3] |
| context: the same review found more adverse effects with trazodone | confirmed | the abstract reports higher odds of blurred vision (OR 17.50, 95% CI 2.28-134.02), somnolence (OR 7.34, 95% CI 2.91-18.50) and sedation (OR 6.53) with trazodone. the authors say the benefits 'must be weighed against a higher risk of adverse effects'. the confidence interval for blurred vision is very wide. [1][2] |
both directions
for the speaker: the central number matches the published abstract: an SMD of 0.365 on the Hamilton scale, statistically significant, from a 2026 GRADE-assessed systematic review and meta-analysis of randomized trials in people with depression. the speaker's word "controls" is as vague as the abstract's own wording, so it does not claim more than the record shows. the FDA label lists major depressive disorder as trazodone's approved use, so the finding fits the drug's established indication.
against: the trial count in the claim sentence ("eight trials") is not in the abstract and we could not read the full text. the abstract does not say whether the comparison groups got placebo or other active drugs. that matters because an SMD against placebo means something different from an SMD against another antidepressant. the review was built around sleep problems in depressed patients, and its main focus was the sleep outcome (PSQI SMD -0.827). Hamilton scores include sleep items, and trazodone is sedating, so part of the Hamilton improvement may reflect better sleep rather than better mood. the abstract does not split this out. the same review found clearly more somnolence, sedation and blurred vision with trazodone. the speaker's quote did not mention these.
what this cannot say
we read only the PubMed abstract and the publisher's landing page. the full text, forest plots, heterogeneity statistics, GRADE certainty rating for the Hamilton outcome, and the list of included trials were behind a paywall and are not part of this check. the PubMed record gives no GRADE rating for any outcome even though the title says "GRADE-assessed". an SMD pooled across trials with different comparators, doses and durations cannot tell any one person how much they would improve. ten trials and about a thousand participants is a modest evidence base. our verdict on the trial count reflects what we could reach, not evidence that the count is wrong.
sources, each one fetched and read
- Hameed AK, et al. The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials. Psychopharmacology (Berl). 2026;243(3):457-473. PMID 41081841. doi:10.1007/s00213-025-06910-y (PubMed record via NCBI E-utilities) What we read there: ten RCTs, 1,029 participants; trazodone 'reduced depression severity (Hamilton Depression Rating Scale: SMD = -0.365, 95% CI: -0.480 to -0.249, p < 0.001)'; PSQI SMD -0.827 (95% CI -1.331 to -0.323); blurred vision OR 17.50, somnolence OR 7.34, sedation OR 6.53; searched PubMed, Scopus, Cochrane Library, PsycInfo and Web of Science to February 2025 Fetched 2026-10-12 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/41081841/
- Psychopharmacology (Springer) publisher landing page for doi:10.1007/s00213-025-06910-y, 2026 What we read there: abstract repeats the Hamilton SMD -0.365 (95% CI -0.480 to -0.249) across ten RCTs with 1,029 participants; full text, comparator details and the GRADE ratings for each outcome are paywalled Fetched 2026-10-12 (HTTP 200). https://link.springer.com/article/10.1007/s00213-025-06910-y?error=cookies_not_supported&code=48a8d2aa-e120-4b74-8f36-c6b751be4c47
- US FDA, openFDA drug label endpoint, trazodone hydrochloride tablets (NDC 50090-6603-0) What we read there: 'Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.' efficacy 'established from inpatient and outpatient trials of the trazodone immediate release formulation' Fetched 2026-10-12 (HTTP 200). https://api.fda.gov/drug/label.json?search=openfda.generic_name:"TRAZODONE+HYDROCHLORIDE"&limit=1
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam